FDA Approves First Drug to Treat Rare Metabolic Disorder
SILVER SPRING, Md., Nov. 23, 2020 /PRNewswire/ -- Today, the Food and Drug Administration approved Oxlumo (lumasiran) as the first treatment for primary hyperoxaluria type 1 (PH1), a rare genetic…
REGENXBIO to Present at Upcoming Investor Conferences
ROCKVILLE, Md., Nov. 23, 2020 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary…
FDA Expands Approval of Influenza Treatment to Post-Exposure Prevention
SILVER SPRING, Md., Nov. 23, 2020 /PRNewswire/ -- Today, the Food and Drug Administration expanded the approved indication for Xofluza (baloxavir marboxil) to include post-exposure prevention of influenza (flu) for patients…